Bank of America Corporation reaffirmed their buy rating on shares of Catalent Inc (NASDAQ:CTLT) in a research report report published on Friday, July 21st. The firm currently has a $38.00 price objective on the stock, up from their previous price objective of $37.00.
A number of other equities analysts have also recently commented on the company. Zacks Investment Research upgraded Catalent from a sell rating to a buy rating and set a $39.00 target price for the company in a report on Tuesday, July 4th. BidaskClub cut Catalent from a strong-buy rating to a buy rating in a report on Tuesday, June 27th. William Blair upgraded Catalent from a market perform rating to an outperform rating in a report on Monday, May 15th. Finally, TheStreet upgraded Catalent from a c rating to a b- rating in a report on Wednesday, April 19th. Five investment analysts have rated the stock with a hold rating and five have given a buy rating to the company. The stock currently has a consensus rating of Buy and a consensus price target of $32.00.
Catalent (CTLT) traded up 1.05% during mid-day trading on Friday, reaching $34.55. 3,170,948 shares of the company’s stock traded hands. Catalent has a 12 month low of $21.83 and a 12 month high of $38.73. The stock has a market cap of $4.32 billion and a P/E ratio of 40.69. The company has a 50 day moving average price of $35.16 and a 200-day moving average price of $32.11.
ILLEGAL ACTIVITY NOTICE: “Catalent Inc (CTLT) Rating Reiterated by Bank of America Corporation” was posted by BNB Daily and is owned by of BNB Daily. If you are viewing this report on another website, it was illegally copied and republished in violation of US and international copyright & trademark laws. The original version of this report can be accessed at https://www.baseball-news-blog.com/2017/08/19/catalent-inc-ctlt-earns-buy-rating-from-bank-of-america-corporation-updated-updated-updated.html.
In related news, SVP Christine Dolan sold 745 shares of the company’s stock in a transaction dated Tuesday, August 1st. The stock was sold at an average price of $34.85, for a total transaction of $25,963.25. The sale was disclosed in a document filed with the SEC, which can be accessed through this link.
Hedge funds and other institutional investors have recently made changes to their positions in the stock. BlackRock Inc. raised its position in shares of Catalent by 15.2% in the second quarter. BlackRock Inc. now owns 17,512,661 shares of the company’s stock valued at $614,695,000 after buying an additional 2,316,849 shares in the last quarter. Vanguard Group Inc. increased its stake in Catalent by 3.8% in the second quarter. Vanguard Group Inc. now owns 10,119,431 shares of the company’s stock valued at $355,192,000 after buying an additional 369,526 shares during the last quarter. Janus Henderson Group PLC purchased a new stake in Catalent during the second quarter valued at $239,629,000. Schroder Investment Management Group increased its stake in Catalent by 8.4% in the first quarter. Schroder Investment Management Group now owns 5,143,664 shares of the company’s stock valued at $146,646,000 after buying an additional 400,219 shares during the last quarter. Finally, JPMorgan Chase & Co. increased its stake in Catalent by 4.6% in the second quarter. JPMorgan Chase & Co. now owns 5,139,690 shares of the company’s stock valued at $180,403,000 after buying an additional 226,705 shares during the last quarter.
Catalent, Inc provides delivery technologies and development solutions for drugs, biologics, and consumer and animal health products. Its segments include Softgel Technologies, Drug Delivery Solutions and Clinical Supply Services. The Softgel Technologies segment is engaged in the formulation, development and manufacturing of prescription and consumer health soft capsules or softgels.
Receive News & Ratings for Catalent Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalent Inc and related companies with MarketBeat.com's FREE daily email newsletter.